{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T02:25:47Z","timestamp":1794709547024,"version":"4.9.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:00:00Z","timestamp":1574121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T00:00:00Z","timestamp":1574121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The most common histological subtypes of cutaneous melanoma include superficial spreading and nodular melanoma. However, the spectrum of somatic mutations developed in those lesions and all potential druggable targets have not yet been fully elucidated. We present the results of a sequence capture NGS analysis of 114 primary nodular and superficial spreading melanomas identifying driver mutations using biostatistical, immunohistochemical and\/or functional approach. The spectrum and frequency of pathogenic or likely pathogenic variants were identified across 54 evaluated genes, including 59 novel mutations, and the newly identified <jats:italic>TP53<\/jats:italic> loss-of-function mutations p.(L194P) and p.(R280K). Frequently mutated genes most commonly affected the MAPK pathway, followed by chromatin remodeling, and cell cycle regulation. Frequent aberrations were also detected in the genes coding for proteins involved in DNA repair and the regulation and modification of cellular tight junctions. Furthermore, relatively frequent mutations were described in <jats:italic>KDR<\/jats:italic> and <jats:italic>MET<\/jats:italic>, which represent potential clinically important targets. Those results suggest that with the development of new therapeutic possibilities, not only <jats:italic>BRAF<\/jats:italic> testing, but complex molecular testing of cutaneous melanoma may become an integral part of the decision process concerning the treatment of patients with melanoma.<\/jats:p>","DOI":"10.1038\/s41598-019-53636-x","type":"journal-article","created":{"date-parts":[[2019,11,19]],"date-time":"2019-11-19T11:04:13Z","timestamp":1574161453000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["A comprehensive evaluation of pathogenic mutations in primary cutaneous melanomas, including the identification of novel loss-of-function variants"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8451-4222","authenticated-orcid":false,"given":"Ivana","family":"Ticha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Hojny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romana","family":"Michalkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondrej","family":"Kodet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Krkavcova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikola","family":"Hajkova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristyna","family":"Nemejcova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela","family":"Bartu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radek","family":"Jaksa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miroslav","family":"Dura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madiha","family":"Kanwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andra S.","family":"Martinikova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0987-1238","authenticated-orcid":false,"given":"Libor","family":"Macurek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Zemankova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2050-9667","authenticated-orcid":false,"given":"Zdenek","family":"Kleibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Dundr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,19]]},"reference":[{"key":"53636_CR1","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.hoc.2009.03.013","volume":"23","author":"LM Duncan","year":"2009","unstructured":"Duncan, L. M. The classification of cutaneous melanoma. Hematol Oncol Clin North Am 23, 501\u2013513, ix, https:\/\/doi.org\/10.1016\/j.hoc.2009.03.013 (2009).","journal-title":"Hematol Oncol Clin North Am"},{"key":"53636_CR2","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","unstructured":"Cancer Genome Atlas Network. Genomic Classification of Cutaneous Melanoma. Cell 161, 1681\u20131696, https:\/\/doi.org\/10.1016\/j.cell.2015.05.044 (2015).","journal-title":"Cell"},{"key":"53636_CR3","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nature22071","volume":"545","author":"NK Hayward","year":"2017","unstructured":"Hayward, N. K. et al. Whole-genome landscapes of major melanoma subtypes. Nature 545, 175\u2013180, https:\/\/doi.org\/10.1038\/nature22071 (2017).","journal-title":"Nature"},{"key":"53636_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","volume":"150","author":"E Hodis","year":"2012","unstructured":"Hodis, E. et al. A landscape of driver mutations in melanoma. Cell 150, 251\u2013263, https:\/\/doi.org\/10.1016\/j.cell.2012.06.024 (2012).","journal-title":"Cell"},{"key":"53636_CR5","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/ng.3361","volume":"47","author":"M Krauthammer","year":"2015","unstructured":"Krauthammer, M. et al. Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nat Genet 47, 996\u20131002, https:\/\/doi.org\/10.1038\/ng.3361 (2015).","journal-title":"Nat Genet"},{"key":"53636_CR6","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11912-012-0249-5","volume":"14","author":"JM Mehnert","year":"2012","unstructured":"Mehnert, J. M. & Kluger, H. M. Driver mutations in melanoma: lessons learned from bench-to-bedside studies. Curr Oncol Rep 14, 449\u2013457, https:\/\/doi.org\/10.1007\/s11912-012-0249-5 (2012).","journal-title":"Curr Oncol Rep"},{"key":"53636_CR7","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","volume":"373","author":"AH Shain","year":"2015","unstructured":"Shain, A. H. et al. The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med 373, 1926\u20131936, https:\/\/doi.org\/10.1056\/NEJMoa1502583 (2015).","journal-title":"N Engl J Med"},{"key":"53636_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-018-0733-7","volume":"20","author":"G Palmieri","year":"2018","unstructured":"Palmieri, G. et al. Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches. Curr Oncol Rep 20, 86, https:\/\/doi.org\/10.1007\/s11912-018-0733-7 (2018).","journal-title":"Curr Oncol Rep"},{"key":"53636_CR9","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/pcmr.12459","volume":"29","author":"T Zhang","year":"2016","unstructured":"Zhang, T., Dutton-Regester, K., Brown, K. M. & Hayward, N. K. The genomic landscape of cutaneous melanoma. Pigment Cell Melanoma Res 29, 266\u2013283, https:\/\/doi.org\/10.1111\/pcmr.12459 (2016).","journal-title":"Pigment Cell Melanoma Res"},{"key":"53636_CR10","doi-asserted-by":"publisher","first-page":"584","DOI":"10.3389\/fonc.2018.00584","volume":"8","author":"X Zhao","year":"2018","unstructured":"Zhao, X. et al. The Prognostic Significance of Low-Frequency Somatic Mutations in Metastatic Cutaneous Melanoma. Front Oncol 8, 584, https:\/\/doi.org\/10.3389\/fonc.2018.00584 (2018).","journal-title":"Front Oncol"},{"key":"53636_CR11","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/jid.2014.366","volume":"135","author":"AE Siroy","year":"2015","unstructured":"Siroy, A. E. et al. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma. J Invest Dermatol 135, 508\u2013515, https:\/\/doi.org\/10.1038\/jid.2014.366 (2015).","journal-title":"J Invest Dermatol"},{"key":"53636_CR12","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.pathol.2018.08.004","volume":"50","author":"J Leichsenring","year":"2018","unstructured":"Leichsenring, J. et al. Genetic profiling of melanoma in routine diagnostics: assay performance and molecular characteristics in a consecutive series of 274 cases. Pathology 50, 703\u2013710, https:\/\/doi.org\/10.1016\/j.pathol.2018.08.004 (2018).","journal-title":"Pathology"},{"key":"53636_CR13","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1038\/ng.2359","volume":"44","author":"M Krauthammer","year":"2012","unstructured":"Krauthammer, M. et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet 44, 1006\u20131014, https:\/\/doi.org\/10.1038\/ng.2359 (2012).","journal-title":"Nat Genet"},{"key":"53636_CR14","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/ng.1026","volume":"44","author":"SI Nikolaev","year":"2011","unstructured":"Nikolaev, S. I. et al. Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma. Nat Genet 44, 133\u2013139, https:\/\/doi.org\/10.1038\/ng.1026 (2011).","journal-title":"Nat Genet"},{"key":"53636_CR15","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1111\/bjd.13626","volume":"172","author":"PV Gumaste","year":"2015","unstructured":"Gumaste, P. V. et al. Skin cancer risk in BRCA1\/2 mutation carriers. Br J Dermatol 172, 1498\u20131506, https:\/\/doi.org\/10.1111\/bjd.13626 (2015).","journal-title":"Br J Dermatol"},{"key":"53636_CR16","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/his.13707","volume":"73","author":"K Linos","year":"2018","unstructured":"Linos, K. & Tafe, L. J. Isocitrate dehydrogenase 1 mutations in melanoma frequently co-occur with NRAS mutations. Histopathology 73, 963\u2013968, https:\/\/doi.org\/10.1111\/his.13707 (2018).","journal-title":"Histopathology"},{"key":"53636_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/ng.2523","volume":"45","author":"JW Harbour","year":"2013","unstructured":"Harbour, J. W. et al. Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet 45, 133\u2013135, https:\/\/doi.org\/10.1038\/ng.2523 (2013).","journal-title":"Nat Genet"},{"key":"53636_CR18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jphotobiol.2018.06.005","volume":"185","author":"G Emri","year":"2018","unstructured":"Emri, G. et al. Ultraviolet radiation-mediated development of cutaneous melanoma: An update. J Photochem Photobiol B 185, 169\u2013175, https:\/\/doi.org\/10.1016\/j.jphotobiol.2018.06.005 (2018).","journal-title":"J Photochem Photobiol B"},{"key":"53636_CR19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1146\/annurev-pathol-012513-104658","volume":"9","author":"BC Bastian","year":"2014","unstructured":"Bastian, B. C. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol 9, 239\u2013271, https:\/\/doi.org\/10.1146\/annurev-pathol-012513-104658 (2014).","journal-title":"Annu Rev Pathol"},{"key":"53636_CR20","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1126\/science.1253735","volume":"346","author":"JA Lo","year":"2014","unstructured":"Lo, J. A. & Fisher, D. E. The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. Science 346, 945\u2013949, https:\/\/doi.org\/10.1126\/science.1253735 (2014).","journal-title":"Science"},{"key":"53636_CR21","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1093\/mutage\/gev073","volume":"30","author":"S Nik-Zainal","year":"2015","unstructured":"Nik-Zainal, S. et al. The genome as a record of environmental exposure. Mutagenesis 30, 763\u2013770, https:\/\/doi.org\/10.1093\/mutage\/gev073 (2015).","journal-title":"Mutagenesis"},{"key":"53636_CR22","doi-asserted-by":"publisher","unstructured":"Lattanzi, M. et al. Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy. J Natl Cancer Inst, https:\/\/doi.org\/10.1093\/jnci\/djy086 (2018).","DOI":"10.1093\/jnci\/djy086"},{"key":"53636_CR23","doi-asserted-by":"publisher","first-page":"4589","DOI":"10.1158\/1078-0432.CCR-13-0398","volume":"19","author":"VJ Mar","year":"2013","unstructured":"Mar, V. J. et al. BRAF\/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage. Clin Cancer Res 19, 4589\u20134598, https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0398 (2013).","journal-title":"Clin Cancer Res"},{"key":"53636_CR24","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10549-006-9406-6","volume":"104","author":"J Prokopcova","year":"2007","unstructured":"Prokopcova, J., Kleibl, Z., Banwell, C. M. & Pohlreich, P. The role of ATM in breast cancer development. Breast Cancer Res Treat 104, 121\u2013128, https:\/\/doi.org\/10.1007\/s10549-006-9406-6 (2007).","journal-title":"Breast Cancer Res Treat"},{"key":"53636_CR25","doi-asserted-by":"publisher","first-page":"4886","DOI":"10.1093\/hmg\/ddx368","volume":"26","author":"AM Goldstein","year":"2017","unstructured":"Goldstein, A. M. et al. Rare germline variants in known melanoma susceptibility genes in familial melanoma. Hum Mol Genet 26, 4886\u20134895, https:\/\/doi.org\/10.1093\/hmg\/ddx368 (2017).","journal-title":"Hum Mol Genet"},{"key":"53636_CR26","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/gcc.20581","volume":"47","author":"MK Korhonen","year":"2008","unstructured":"Korhonen, M. K., Vuorenmaa, E. & Nystrom, M. The first functional study of MLH3 mutations found in cancer patients. Genes Chromosomes Cancer 47, 803\u2013809, https:\/\/doi.org\/10.1002\/gcc.20581 (2008).","journal-title":"Genes Chromosomes Cancer"},{"key":"53636_CR27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/bjc.2017.433","volume":"118","author":"CE Wu","year":"2018","unstructured":"Wu, C. E. et al. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma. Br J Cancer 118, 495\u2013508, https:\/\/doi.org\/10.1038\/bjc.2017.433 (2018).","journal-title":"Br J Cancer"},{"key":"53636_CR28","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3978\/j.issn.2305-5839.2015.08.06","volume":"3","author":"N Karachaliou","year":"2015","unstructured":"Karachaliou, N. et al. Melanoma: oncogenic drivers and the immune system. Ann Transl Med 3, 265, https:\/\/doi.org\/10.3978\/j.issn.2305-5839.2015.08.06 (2015).","journal-title":"Ann Transl Med"},{"key":"53636_CR29","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ccr.2013.08.018","volume":"24","author":"J Caramel","year":"2013","unstructured":"Caramel, J. et al. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell 24, 466\u2013480, https:\/\/doi.org\/10.1016\/j.ccr.2013.08.018 (2013).","journal-title":"Cancer Cell"},{"key":"53636_CR30","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1038\/cdd.2014.44","volume":"21","author":"G Denecker","year":"2014","unstructured":"Denecker, G. et al. Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. Cell Death Differ 21, 1250\u20131261, https:\/\/doi.org\/10.1038\/cdd.2014.44 (2014).","journal-title":"Cell Death Differ"},{"key":"53636_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrm1310","volume":"5","author":"LE Maquat","year":"2004","unstructured":"Maquat, L. E. Nonsense-mediated mRNA decay: splicing, translation and mRNP dynamics. Nat Rev Mol Cell Biol 5, 89\u201399, https:\/\/doi.org\/10.1038\/nrm1310 (2004).","journal-title":"Nat Rev Mol Cell Biol"},{"key":"53636_CR32","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/humu.23035","volume":"37","author":"L Bouaoun","year":"2016","unstructured":"Bouaoun, L. et al. TP53 Variations in Human Cancers: New Lessons from the IARC TP53 Database and Genomics Data. Hum Mutat 37, 865\u2013876, https:\/\/doi.org\/10.1002\/humu.23035 (2016).","journal-title":"Hum Mutat"},{"key":"53636_CR33","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/gcc.20202","volume":"44","author":"A Molven","year":"2005","unstructured":"Molven, A. et al. A large Norwegian family with inherited malignant melanoma, multiple atypical nevi, and CDK4 mutation. Genes Chromosomes Cancer 44, 10\u201318, https:\/\/doi.org\/10.1002\/gcc.20202 (2005).","journal-title":"Genes Chromosomes Cancer"},{"key":"53636_CR34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1136\/jmg.2005.033878","volume":"43","author":"SV Tavtigian","year":"2006","unstructured":"Tavtigian, S. V. et al. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 43, 295\u2013305, https:\/\/doi.org\/10.1136\/jmg.2005.033878 (2006).","journal-title":"J Med Genet"},{"key":"53636_CR35","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1056\/NEJMoa050092","volume":"353","author":"JA Curtin","year":"2005","unstructured":"Curtin, J. A. et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 353, 2135\u20132147, https:\/\/doi.org\/10.1056\/NEJMoa050092 (2005).","journal-title":"N Engl J Med"},{"key":"53636_CR36","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1111\/j.1755-148X.2011.00837.x","volume":"24","author":"J Bauer","year":"2011","unstructured":"Bauer, J. et al. BRAF mutations in cutaneous melanoma are independently associated with age, anatomic site of the primary tumor, and the degree of solar elastosis at the primary tumor site. Pigment Cell Melanoma Res 24, 345\u2013351, https:\/\/doi.org\/10.1111\/j.1755-148X.2011.00837.x (2011).","journal-title":"Pigment Cell Melanoma Res"},{"key":"53636_CR37","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.1002\/cncr.26724","volume":"118","author":"JA Jakob","year":"2012","unstructured":"Jakob, J. A. et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118, 4014\u20134023, https:\/\/doi.org\/10.1002\/cncr.26724 (2012).","journal-title":"Cancer"},{"key":"53636_CR38","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1200\/JCO.2010.32.4327","volume":"29","author":"GV Long","year":"2011","unstructured":"Long, G. V. et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29, 1239\u20131246, https:\/\/doi.org\/10.1200\/JCO.2010.32.4327 (2011).","journal-title":"J Clin Oncol"},{"key":"53636_CR39","doi-asserted-by":"publisher","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","volume":"27","author":"CM Balch","year":"2009","unstructured":"Balch, C. M. et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 27, 6199\u20136206, https:\/\/doi.org\/10.1200\/JCO.2009.23.4799 (2009).","journal-title":"J Clin Oncol"},{"key":"53636_CR40","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1016\/j.humpath.2013.02.022","volume":"44","author":"AA Brozyna","year":"2013","unstructured":"Brozyna, A. A. et al. Melanogenesis affects overall and disease-free survival in patients with stage III and IV melanoma. Hum Pathol 44, 2071\u20132074, https:\/\/doi.org\/10.1016\/j.humpath.2013.02.022 (2013).","journal-title":"Hum Pathol"},{"key":"53636_CR41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.abb.2014.06.030","volume":"563","author":"A Slominski","year":"2014","unstructured":"Slominski, A. et al. The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1alpha expression and HIF-dependent attendant pathways. Arch Biochem Biophys 563, 79\u201393, https:\/\/doi.org\/10.1016\/j.abb.2014.06.030 (2014).","journal-title":"Arch Biochem Biophys"},{"key":"53636_CR42","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1097\/CCO.0000000000000405","volume":"29","author":"IP Silva","year":"2017","unstructured":"Silva, I. P. & Long, G. V. Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice. Curr Opin Oncol 29, 484\u2013492, https:\/\/doi.org\/10.1097\/CCO.0000000000000405 (2017).","journal-title":"Curr Opin Oncol"},{"key":"53636_CR43","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1002\/cam4.1001","volume":"6","author":"JP da Silveira Nogueira Lima","year":"2017","unstructured":"da Silveira Nogueira Lima, J. P., Georgieva, M., Haaland, B. & de Lima Lopes, G. A systematic review and network meta-analysis of immunotherapy and targeted therapy for advanced melanoma. Cancer Med 6, 1143\u20131153, https:\/\/doi.org\/10.1002\/cam4.1001 (2017).","journal-title":"Cancer Med"},{"key":"53636_CR44","doi-asserted-by":"publisher","unstructured":"Wu, C. E. et al. ATM Dependent DUSP6 Modulation of p53 Involved in Synergistic Targeting of MAPK and p53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma. Cancers (Basel) 11, https:\/\/doi.org\/10.3390\/cancers11010003 (2018).","DOI":"10.3390\/cancers11010003"},{"key":"53636_CR45","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1038\/onc.2016.486","volume":"36","author":"HS Kim","year":"2017","unstructured":"Kim, H. S. et al. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK\/PI3K inhibition or MEK\/CDK4\/6 inhibition. Oncogene 36, 3334\u20133345, https:\/\/doi.org\/10.1038\/onc.2016.486 (2017).","journal-title":"Oncogene"},{"key":"53636_CR46","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1002\/humu.20481","volume":"28","author":"T Hocker","year":"2007","unstructured":"Hocker, T. & Tsao, H. Ultraviolet radiation and melanoma: a systematic review and analysis of reported sequence variants. Hum Mutat 28, 578\u2013588, https:\/\/doi.org\/10.1002\/humu.20481 (2007).","journal-title":"Hum Mutat"},{"key":"53636_CR47","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/cas.13156","volume":"108","author":"K Matsumoto","year":"2017","unstructured":"Matsumoto, K., Umitsu, M., De Silva, D. M., Roy, A. & Bottaro, D. P. Hepatocyte growth factor\/MET in cancer progression and biomarker discovery. Cancer Sci 108, 296\u2013307, https:\/\/doi.org\/10.1111\/cas.13156 (2017).","journal-title":"Cancer Sci"},{"key":"53636_CR48","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/pcmr.12757","volume":"32","author":"K Nemejcova","year":"2019","unstructured":"Nemejcova, K. et al. Comparison of five different scoring methods in the evaluation of inflammatory infiltration (tumor-infiltrating lymphocytes) in superficial spreading and nodular melanoma. Pigment Cell Melanoma Res 32, 412\u2013423, https:\/\/doi.org\/10.1111\/pcmr.12757 (2019).","journal-title":"Pigment Cell Melanoma Res"},{"key":"53636_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol 17, 122, https:\/\/doi.org\/10.1186\/s13059-016-0974-4 (2016).","journal-title":"Genome Biol"},{"key":"53636_CR50","doi-asserted-by":"publisher","first-page":"D607","DOI":"10.1093\/nar\/gky1131","volume":"47","author":"D Szklarczyk","year":"2019","unstructured":"Szklarczyk, D. et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res 47, D607\u2013D613, https:\/\/doi.org\/10.1093\/nar\/gky1131 (2019).","journal-title":"Nucleic Acids Res"},{"key":"53636_CR51","doi-asserted-by":"publisher","first-page":"672","DOI":"10.7150\/ijbs.4283","volume":"8","author":"B Gu","year":"2012","unstructured":"Gu, B. & Zhu, W. G. Surf the post-translational modification network of p53 regulation. Int J Biol Sci 8, 672\u2013684, https:\/\/doi.org\/10.7150\/ijbs.4283 (2012).","journal-title":"Int J Biol Sci"},{"key":"53636_CR52","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1126\/science.1092472","volume":"303","author":"LT Vassilev","year":"2004","unstructured":"Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844\u2013848, https:\/\/doi.org\/10.1126\/science.1092472 (2004).","journal-title":"Science"},{"key":"53636_CR53","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.15252\/embj.201696082","volume":"36","author":"H Jaiswal","year":"2017","unstructured":"Jaiswal, H. et al. ATM\/Wip1 activities at chromatin control Plk1 re-activation to determine G2 checkpoint duration. EMBO J 36, 2161\u20132176, https:\/\/doi.org\/10.15252\/embj.201696082 (2017).","journal-title":"EMBO J"},{"key":"53636_CR54","doi-asserted-by":"publisher","first-page":"14458","DOI":"10.18632\/oncotarget.7363","volume":"7","author":"S Pechackova","year":"2016","unstructured":"Pechackova, S. et al. Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3. Oncotarget 7, 14458\u201314475, https:\/\/doi.org\/10.18632\/oncotarget.7363 (2016).","journal-title":"Oncotarget"},{"key":"53636_CR55","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1002\/path.2744","volume":"222","author":"M Kobel","year":"2010","unstructured":"Kobel, M. et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol 222, 191\u2013198, https:\/\/doi.org\/10.1002\/path.2744 (2010).","journal-title":"J Pathol"},{"key":"53636_CR56","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26040-0","volume":"8","author":"N Hajkova","year":"2018","unstructured":"Hajkova, N. et al. Germline mutation in the TP53 gene in uveal melanoma. Sci Rep 8, 7618, https:\/\/doi.org\/10.1038\/s41598-018-26040-0 (2018).","journal-title":"Sci Rep"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53636-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53636-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53636-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T16:08:38Z","timestamp":1671293318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-53636-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,19]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["53636"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-53636-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,19]]},"assertion":[{"value":"11 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17050"}}